Wall Street brokerages expect Xencor Inc (NASDAQ:XNCR) to announce sales of $15.65 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Xencor’s earnings. The lowest sales estimate is $10.30 million and the highest is $21.00 million. Xencor reported sales of $6.44 million in the same quarter last year, which would suggest a positive year over year growth rate of 143%. The business is scheduled to announce its next earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Xencor will report full-year sales of $15.65 million for the current year, with estimates ranging from $25.30 million to $45.77 million. For the next year, analysts forecast that the business will report sales of $25.33 million per share, with estimates ranging from $19.80 million to $36.20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Xencor.
XNCR has been the topic of a number of recent analyst reports. BidaskClub raised shares of Xencor from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Zacks Investment Research reaffirmed a “sell” rating on shares of Xencor in a research report on Saturday, January 13th. Cantor Fitzgerald started coverage on shares of Xencor in a research report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 target price on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 target price on shares of Xencor in a research report on Sunday, November 12th. Finally, ValuEngine lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $30.80.
In other Xencor news, major shareholder John S. Stafford III purchased 9,215 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were purchased at an average price of $20.76 per share, for a total transaction of $191,303.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III purchased 5,349 shares of the firm’s stock in a transaction on Friday, November 24th. The shares were acquired at an average price of $19.85 per share, for a total transaction of $106,177.65. The disclosure for this purchase can be found here. Insiders have acquired 36,153 shares of company stock worth $731,583 in the last quarter. Corporate insiders own 4.14% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can boosted its stake in Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Xencor during the third quarter worth $201,000. Legal & General Group Plc boosted its stake in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in Xencor during the fourth quarter worth $205,000. Finally, Citadel Advisors LLC acquired a new stake in Xencor during the second quarter worth $224,000. Hedge funds and other institutional investors own 77.33% of the company’s stock.
Xencor (XNCR) traded up $0.55 during midday trading on Friday, reaching $22.25. 143,657 shares of the company’s stock were exchanged, compared to its average volume of 161,723. The firm has a market capitalization of $1,019.05, a PE ratio of -21.70 and a beta of 1.97. Xencor has a 1 year low of $18.55 and a 1 year high of $28.64.
WARNING: “Xencor Inc (XNCR) Expected to Announce Quarterly Sales of $15.65 Million” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/12/xencor-inc-xncr-expected-to-announce-quarterly-sales-of-15-65-million.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Get a free copy of the Zacks research report on Xencor (XNCR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.